Beurs.nl monitor iconMarkt Monitor
  • AEX +1,73 915,68 +0,19%
  • DE40 0,00 23.154,57 0,00%
  • US500^ -12,46 5.665,59 -0,22%
  • US30^ -83,50 41.775,70 -0,20%
  • EUR/USD +0,00 1,0939 +0,16%
  • WTI +0,68 67,92 +1,01%
  • Gold spot +18,33 3.018,66 +0,61%

Forum Arrowhead Research geopend

8.727 Posts
Pagina: «« 1 ... 432 433 434 435 436 437 | Laatste | Omlaag ↓
  1. forum rang 5 Hulskof 26 februari 2025 08:35
    quote:

    nb schreef op 26 februari 2025 07:10:

    Wat zou het voordeel kunnen zijn tov de medicijnen die er al zijn van eli lily en novo?
    Behoud van spiermassa uiteraard. Het volgende is wellicht ook interessant:

    Further thought...Even the "analysts" don't suggest, let alone trumpet, the collaboration with Eli Lilly on tirzepitide. That is NOT insignificant. ARWR didn't just whimsically select Tir. This is the distant number 2 drug in the space but projected to overtake Novo's Ozempic/Wegovey by 2030. If the net benefit of the drug is a 50% fat reduction with no material lean muscle loss, this could be the biggest drug (combi) on the market in 5-7 years. It dwarfs the CVD portfolio which is potentially large itself. Might explain why lung appears to all of a sudden be on the partnership/for sale block...to fund obesity. We know obesity is a pet of CAs going back to pre-siRNA days. Might have a strategy evolving here. But who the F- knows.
  2. forum rang 6 Tom3 26 februari 2025 14:42
    quote:

    Hulskof schreef op 26 februari 2025 08:35:

    [...]

    Behoud van spiermassa uiteraard. Het volgende is wellicht ook interessant:

    Further thought...Even the "analysts" don't suggest, let alone trumpet, the collaboration with Eli Lilly on tirzepitide. That is NOT insignificant. ARWR didn't just whimsically select Tir. This is the distant number 2 drug in the space but projected to overtake Novo's Ozempic/Wegovey by 2030. If the net benefit of the drug is a 50% fat reduction with no material lean muscle loss, this could be the biggest drug (combi) on the market in 5-7 years. It dwarfs the CVD portfolio which is potentially large itself. Might explain why lung appears to all of a sudden be on the partnership/for sale block...to fund obesity. We know obesity is a pet of CAs going back to pre-siRNA days. Might have a strategy evolving here. But who the F- knows.
    @Hulskof, klinkt aannemelijk maar wat is je bron? Wordt er gesuggereerd dat Lilly een bod zou kunnen uitbrengen op ARWR? De bedragen die met obesitas verdiend kunnen worden zijn op zich al duizelingwekkend, laat staan een combi die de ook nog een keer het risico op diabetes #2 zou kunnen verkleinen. Heeft Novo dubbele pech.
  3. forum rang 5 Hulskof 26 februari 2025 17:18
    quote:

    Tom3 schreef op 26 februari 2025 14:42:

    [...]

    @Hulskof, klinkt aannemelijk maar wat is je bron? Wordt er gesuggereerd dat Lilly een bod zou kunnen uitbrengen op ARWR? De bedragen die met obesitas verdiend kunnen worden zijn op zich al duizelingwekkend, laat staan een combi die de ook nog een keer het risico op diabetes #2 zou kunnen verkleinen. Heeft Novo dubbele pech.
    Van onze schreeuwlelijk Holden op zijn Discord.
    Nee, geen suggestie van een overname. In het persbericht van Arrowhead staat expliciet de combi met Lilly's Tirzepitide vermeld. Wellicht dus met een bepaalde intentie van CA...
  4. Missolapola 10 maart 2025 13:28
    Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
    March 10, 2025

    - ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria

    - Mean sustained reductions in C3 of =87%, AH50 of =76%, Wieslab AP of =89% through week 24

    - Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24

    PASADENA, Calif.--(BUSINESS WIRE)--Mar. 10, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025.

    Select Phase 1/2 Study Results

    Patients with IgA nephropathy (IgAN) (n=14) received subcutaneous doses of ARO-C3 (400 mg) on Days 1, 29, and 113 and were followed through Day 169
    Pharmacodynamic effects
    Maximum mean reduction in C3 of 89% and mean sustained reduction of greater than 87% from baseline through week 24
    Maximum mean reduction in serum AH50 (alternative pathway hemolytic assay) of 85% and mean sustained reduction greater than 76% from baseline through week 24
    Maximum mean reduction in Wieslab AP (alternative pathway) of 100% and mean sustained reduction greater than 89% from baseline through week 24
    Duration of effect supportive of once every three month or less frequent subcutaneous dosing in later stage studies
    Effects on proteinuria
    Mean reduction in spot UPCR of 41% and maximum individual reduction of 89% from baseline by week 24
    Safety and Tolerability
    ARO-C3 was generally well-tolerated in patients with IgAN
    No serious or severe treatment emergent adverse events (TEAE) and no TEAEs that led to study or study drug discontinuation
    The only TEAEs reported in more than 1 subject were headache, cough, and nasopharyngitis
    No infections with encapsulated organisms
    “ARO-C3 has shown potent and consistent results in normal healthy volunteers and now in patients with IgA nephropathy, including up to 89% mean reduction of complement component 3 (C3), which led to reductions of 85% in AH50 and 100% in Wieslab AP, both markers of alternative pathway complement activity. Such durable and near complete inhibition of the alternative complement pathway achieved with infrequent subcutaneous dose administration may be advantageous,” said James Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D. “In addition, proteinuria, a surrogate marker of renal injury in IgAN, improved with a 41% reduction in spot UPCR. We look forward to sharing more data from the Phase 1/2 clinical study of ARO-C3 at an upcoming medical meeting in 2025.”
  5. forum rang 5 Hulskof 10 maart 2025 14:37
    quote:

    wijzerplaat schreef op 7 maart 2025 10:10:

    Ooit zal het wel iets moeten worden zeker.
    We gaan eerst nog wat verder neerwaarts. Ik vrees dat ze dit tot cash-niveau gaan stampen.
8.727 Posts
Pagina: «« 1 ... 432 433 434 435 436 437 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.103
AB InBev 2 5.530
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.973
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.812
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.792
Aedifica 3 925
Aegon 3.258 323.014
AFC Ajax 538 7.088
Affimed NV 2 6.303
ageas 5.844 109.900
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.254
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.128
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 415
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.657
AMG 971 134.145
AMS 3 73
Amsterdam Commodities 305 6.742
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.033
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.907
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.348
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.575
ASML 1.766 109.623
ASR Nederland 21 4.506
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.741
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.439